Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 9, 2015, Pages 973-985

  Mathey, Emily K ^a   Park, Susanna B ^a,b   Hughes, Richard A C ^c   Pollard, John D ^a   Armati, Patricia J ^a   Barnett, Michael H ^a   Taylor, Bruce V ^d   Dyck, P James B ^e   Kiernan, Matthew C ^a   Lin, Cindy S Y ^f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF TASMANIA   (Australia)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN PROTEIN;

ANTIBODY RESPONSE; BLOOD NERVE BARRIER; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EVOKED SOMATOSENSORY RESPONSE; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; LATENT PERIOD; MYELINATED NERVE; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPIC VARIATION; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT PLANNING; IMMUNOLOGY; MYELIN SHEATH; PATHOLOGY; PHENOTYPE; SCHWANN CELL; T LYMPHOCYTE;

HUMANS; MYELIN SHEATH; PHENOTYPE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SCHWANN CELLS; T-LYMPHOCYTES;

EID: 84940658776     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309697     Document Type: Review

References (169)

1. McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910-13.
2. Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007;78:1349-53.
3. Iijima M, Koike H, Hattori N, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008;79:1040-3.
4. Lunn MP, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999;66:677-80.
5. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014;21:28-33.
6. Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009;39:432-8.
7. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010;17:356-63.
8. Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 2003;250:714-24.
9. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010;15:50-6.
10. Rotta FT, Sussman AT, Bradley WG, et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129-39.
11. Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve 2013;48:727-32.
12. Ohkoshi N, Harada K, Nagata H, et al. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy: clinical features and pathological study of the sural nerves. Eur Neurol 2001;45:241-8.
13. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-8.
14. Lewis RA, Sumner AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982;32:958-64.
15. Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating neuropathy. Brain 1996;119(Pt 3):765-74.
16. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110(Pt 6):1617-30.
17. Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 2010;74:1680-6.
18. Odaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome. J Neurol 2003;250:913-16.
19. Said G, Krarup C. Chronic inflammatory demyelinative polyneuropathy. Handb Clin Neurol 2013;115:403-13.
20. Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst 2014;19:2-13.
21. Oh SJ, Joy JL, Kuruoglu R. "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992;55:677-80.
22. Rajabally YA, Wong SL. Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology. J Clin Neuromuscul Dis 2012;13:149-52.
23. van Dijk GW, Notermans NC, Franssen H, et al. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol 1999;246:1134-9.
24. Sinnreich M, Klein CJ, Daube JR, et al. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004;63:1662-9.
25. Yiannikas C, Vucic S. Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle Nerve 2008;38:1447-54.
26. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615-20.
27. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-24.
28. Larue S, Bombelli F, Viala K, et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011;18:899-905.
29. Sabatelli M, Madia F, Mignogna T, et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 2001;248:772-7.
30. Kimura A, Sakurai T, Koumura A, et al. Motor-dominant chronic inflammatory demyelinating polyneuropathy. J Neurol 2010;257:621-9.
31. Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001;184:57-63.
32. Rajabally YA, Chavada G. Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve 2009;39:206-20.
33. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999;22:560-6.
34. Viala K, Renie L, Maisonobe T, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004;127:2010-17.
35. Verma A, Tandan R, Adesina AM, et al. Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. Acta Neurol Scand 1990;81:516-21.
36. Ayrignac X, Rodrigues BS, Morales R, et al. Focal CIDP presenting as chronic progressive monomelic sensory neuropathy. Muscle Nerve 2013;47: 143-4.
37. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(Suppl):S21-4.
38. Sung JY, Tani J, Park SB, et al. Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain 2014;137:2155-63.
39. Hughes R, Sanders E, Hall S, et al. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992;49:612-16.
40. Oh SJ, Kurokawa K, de Almeida DF, et al. Subacute inflammatory demyelinating polyneuropathy. Neurology 2003;61:1507-12.
41. Rodriguez-Casero MV, Shield LK, Kornberg AJ. Subacute inflammatory demyelinating polyneuropathy in children. Neurology 2005;64:1786-8.
42. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst 2010;15:185-95.
43. Niermeijer JM, Fischer K, Eurelings M, et al. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurology 2010;74:406-12.
44. Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416-24.
45. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123(Pt 4):710-17.
46. Rajabally YA. Neuropathy and paraproteins: review of a complex association. Eur J Neurol 2011;18:1291-8.
47. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994;117(Pt 5):941-7.
48. Suarez GA, Kelly JJ Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology 1993;43:1304-8.
49. Magy L, Chassande B, Maisonobe T, et al. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol 2003;10:677-85.
50. Willison HJ, O'Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;124:1968-77.
51. Nobile-Orazio E, Gallia F, Terenghi F, et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci 2008;266:156-63.
52. Kam C, Balaratnam MS, Purves A, et al. Canomad presenting without ophthalmoplegia and responding to intravenous immunoglobulin. Muscle Nerve 2011;44:829-33.
53. Nasu S, Misawa S, Sekiguchi Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2012;83:476-9.
54. Nobile-Orazio E. Neuropathy and monoclonal gammopathy. In: Said G, Krarup C, eds. Handbook of clinical neurology. Amsterdam: Elsevier, 2013:443-59.
55. Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998;21:1390-7.
56. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst 2010;15:295-301.
57. Arcila-Londono X, Lewis RA. Multifocal Motor Neuropathy. In: Said G, Krarup C, eds. Handbook of clinical neurology. Amsterdam: Elsevier, 2013:429-42.
58. Taylor BV, Dyck PJ, Engelstad J, et al. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 2004;63:129-37.
59. Taylor BV, Wright RA, Harper CM, et al. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-8.
60. Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 1997;49:1289-92.
61. van Schaik IN, Bossuyt PM, Brand A, et al. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology 1995;45:1570-7.
62. Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 2010;75:1961-7.
63. Galban-Horcajo F, Fitzpatrick AM, Hutton AJ, et al. Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol 2013;20:62-70.
64. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005;31:663-80.
65. Willison HJ, Veitch J, Swan AV, et al. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999;6:71-7.
66. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-83.
67. Breiner A, Brannagan TH III. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014;50:40-6.
68. Rajabally YA, Fowle AJ, Van den Bergh PY. Which criteria for research in CIDP? An analysis of current practice. Muscle Nerve 2014. 10.1002/mus.24496 (In press).
69. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-58.
70. Sommer C, Koch S, Lammens M, et al. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005;65:1924-9.
71. Bosboom WM, van den Berg LH, De BL, et al. The diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy. Neurology 1999;53:837-45.
72. Pollard JD, McCombe PA, Baverstock J, et al. Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1986;13:123-34.
73. Schmidt B, Toyka KV, Kiefer R, et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996;19:474-87.
74. Chi LJ, Xu WH, Zhang ZW, et al. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010;15:345-56.
75. Madia F, Frisullo G, Nociti V, et al. pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2009;14:107-17.
76. Hartung HP, Reiners K, Schmidt B, et al. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991;30:48-53.
77. Rentzos M, Angeli AV, Rombos A, et al. Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients. Neurol Res 2012;34:842-6.
78. Gironi M, Saresella M, Marventano I, et al. Distinct cytokine patterns associated with different forms of chronic dysimmune neuropathy. Muscle Nerve 2010;42:864-70.
79. Sainaghi PP, Collimedaglia L, Alciato F, et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010;51:138-43.
80. Misawa S, Kuwabara S, Mori M, et al. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 2001;56:666-9.
81. Press R, Pashenkov M, Jin JP, et al. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Immunol 2003;23:259-67.
82. Kieseier BC, Tani M, Mahad D, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002;125:823-34.
83. Linington C, Lassmann H, Ozawa K, et al. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines. Eur J Immunol 1992;22:1813-17.
84. Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol 1995;37:467-75.
85. Spies JM, Westland KW, Bonner JG, et al. Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain 1995;118(Pt 4):857-68.
86. Spies JM, Pollard JD, Bonner JG, et al. Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol 1995;57:77-84.
87. van den Berg LH, Mollee I, Wokke JH, et al. Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 1995;58:37-42.
88. Mei FJ, Ishizu T, Murai H, et al. Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. J Neurol Sci 2005;228:75-85.
89. Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999;22:30-8.
90. Oka N, Akiguchi I, Nagao M, et al. Expression of endothelial leukocyte adhesion molecule-1 (ELAM-1) in chronic inflammatory demyelinating polyneuropathy. Neurology 1994;44:946-50.
91. Musso AM, Zanusso GL, Bonazzi ML, et al. Increased serum levels of ICAM-1, ELAM-1 and TNF-alpha in inflammatory disorders of the peripheral nervous system. Ital J Neurol Sci 1994;15:267-71.
92. Leppert D, Hughes P, Huber S, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 1999;53:62-70.
93. Kuwabara S, Nakajima M, Matsuda S, et al. Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathy. Neurology 1997;48:874-7.
94. Schneider-Hohendorf T, Schwab N, Uceyler N, et al. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012;78:402-8.
95. Cornblath DR, Griffin DE, Welch D, et al. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J Neuroimmunol 1990;26:113-18.
96. Kiefer R, Dangond F, Mueller M, et al. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J Neurol Neurosurg Psychiatry 2000;69:362-8.
97. Murata K, Dalakas MC. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 2000;123(Pt 8):1660-6.
98. Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma and IL-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci 1999;163:47-52.
99. Kiefer R, Kieseier BC, Stoll G, et al. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 2001;64:109-27.
100. Vital C, Vital A, Lagueny A, et al. Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct Pathol 2000;24:363-9.
101. Steinhoff U, Kaufmann SH. Specific lysis by CD8+ T cells of Schwann cells expressing Mycobacterium leprae antigens. Eur J Immunol 1988;18:969-72.
102. Mausberg AK, Dorok M, Stettner M, et al. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology 2013;80:296-303.
103. Sanvito L, Makowska A, Gregson N, et al. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity 2009;42:667-77.
104. Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2008;13:54-63.
105. Salomon B, Rhee L, Bour-Jordan H, et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 2001;194:677-84.
106. Louvet C, Kabre BG, Davini DW, et al. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med 2009;206:507-14.
107. Su MA, Davini D, Cheng P, et al. Defective autoimmune regulator-dependent central tolerance to myelin protein zero is linked to autoimmune peripheral neuropathy. J Immunol 2012;188:4906-12.
108. Meyer zu HG, Mausberg AK, Cordes S, et al. Thymic epithelium determines a spontaneous chronic neuritis in Icam1tm1JcgrNOD Mice. J Immunol 2014;193:2678-90.
109. Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 1980;37:637-40.
110. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 1988;18:231-44.
111. Yan WX, Taylor J, Ndrias-Kauba S, et al. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000;47:765-75.
112. Heininger K, Liebert UG, Toyka KV, et al. Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci 1984;66:1-14.
113. Yan WX, Archelos JJ, Hartung HP, et al. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:286-92.
114. Allen D, Giannopoulos K, Gray I, et al. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2005;10:174-80.
115. Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry 2007;78:419-22.
116. Khalili-Shirazi A, Atkinson P, Gregson N, et al. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993;46:245-51.
117. Sanvito L, Makowska A, Mahdi-Rogers M, et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2009;80:333-8.
118. Quarles RH, Ilyas AA, Willison HJ. Antibodies to gangliosides and myelin proteins in Guillain-Barré syndrome. Ann Neurol 1990;27(Suppl):S48-52.
119. Kwa MS, van Schaik IN, Brand A, et al. Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol 2001;116:220-5.
120. Melendez-Vasquez C, Redford J, Choudhary PP, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1997;73:124-34.
121. Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 2000;104:139-46.
122. Ritz MF, Lechner-Scott J, Scott RJ, et al. Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies. J Neuroimmunol 2000;104:155-63.
123. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2014;82:879-86.
124. Ng JK, Malotka J, Kawakami N, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 2012;79:2241-8.
125. Kawamura N, Yamasaki R, Yonekawa T, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 2013;81:714-22.
126. Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barré syndrome. J Peripher Nerv Syst 2012;17:62-71.
127. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013;73:370-80.
128. Milner P, Lovelidge CA, Taylor WA, et al. P0 myelin protein produces experimental allergic neuritis in Lewis rats. J Neurol Sci 1987;79:275-85.
129. Kadlubowski M, Hughes RA. Identification of the neuritogen for experimental allergic neuritis. Nature 1979;277:140-1.
130. Gabriel CM, Hughes RA, Moore SE, et al. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain 1998;121(Pt 10):1895-902.
131. Hughes RA, Powell HC, Braheny SL, et al. Endoneurial injection of antisera to myelin antigens. Muscle Nerve 1985;8:516-22.
132. Devaux JJ. Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. Am J Pathol 2012;181:1402-13.
133. Amor V, Feinberg K, Eshed-Eisenbach Y, et al. Long-term maintenance of Na+ channels at nodes of Ranvier depends on glial contact mediated by gliomedin and NrCAM. J Neurosci 2014;34:5089-98.
134. Salzer JL, Brophy PJ, Peles E. Molecular domains of myelinated axons in the peripheral nervous system. Glia 2008;56:1532-40.
135. Thaxton C, Pillai AM, Pribisko AL, et al. In vivo deletion of immunoglobulin domains 5 and 6 in neurofascin (Nfasc) reveals domain-specific requirements in myelinated axons. J Neurosci 2010;30:4868-76.
136. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol 2013;124:1928-34.
137. Chavada G, Willison HJ. Autoantibodies in immune-mediated neuropathies. Curr Opin Neurol 2012;25:550-5.
138. McGonigal R, Rowan EG, Greenshields KN, et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 2010;133:1944-60.
139. Shahrizaila N, Kokubun N, Sawai S, et al. Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology 2014;83:118-24.
140. Sawai S, Satoh M, Mori M, et al. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology 2014;83:113-17.
141. Notturno F, Di FT, Yuki N, et al. Autoantibodies to neurofascin-186 and gliomedin in multifocal motor neuropathy. J Neuroimmunol 2014;276:207-12.
142. Cifuentes-Diaz C, Dubourg O, Irinopoulou T, et al. Nodes of Ranvier and paranodes in chronic acquired neuropathies. PLoS ONE 2011;6:e14533.
143. Doppler K, Werner C, Sommer C. Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies. J Peripher Nerv Syst 2013;18:168-76.
144. Lonigro A, Devaux JJ. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain 2009;132:260-73.
145. Yan W, Nguyen T, Yuki N, et al. Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis. J Neuroimmunol 2014;277:13-17.
146. Davis JQ, Lambert S, Bennett V. Molecular composition of the node of Ranvier: identification of ankyrin-binding cell adhesion molecules neurofascin (mucin+/third FNIII domain-) and NrCAM at nodal axon segments. J Cell Biol 1996;135:1355-67.
147. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007;204:2363-72.
148. Nirula A, Glaser SM, Kalled SL, et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011;23: 119-24.
149. Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA 2013;110:20783-8.
150. Labasque M, Hivert B, Nogales-Gadea G, et al. Specific Contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem 2014;289:7907-18.
151. Lindner M, Ng JK, Hochmeister S, et al. Neurofascin 186 specific autoantibodies induce axonal injury and exacerbate disease severity in experimental autoimmune encephalomyelitis. Exp Neurol 2013;247C:259-66.
152. Charles P, Tait S, Faivre-Sarrailh C, et al. Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol 2002;12:217-20.
153. Rinaldi S, Brennan KM, Kalna G, et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PLoS ONE 2013;8:e82337.
154. Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol 2013;34:453-9.
155. Cappelen-Smith C, Kuwabara S, Lin CS, et al. Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain 2001;124:2439-47.
156. Lin CS, Krishnan AV, Park SB, et al. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011;68:862-9.
157. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011;7:507-17.
158. Tasaki I. Conduction of the nerve impulse. In: Field J, Magoun HW, Hall VE, eds. Handbook of physiology, Section 1, neurophysiology. Washington DC: American Physiological Society, 1959:75-121.
159. Bostock H, Grafe P. Activity-dependent excitability changes in normal and demyelinated rat spinal root axons. J Physiol 1985;365:239-57.
160. Cappelen-Smith C, Kuwabara S, Lin CS, et al. Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2000;48:826-32.
161. Hitomi T, Kaji R, Murase N, et al. Dynamic change of proximal conduction in demyelinating neuropathies: a cervical magnetic stimulation combined with maximum voluntary contraction. Clin Neurophysiol 2007;118:741-50.
162. Straver DC, van den Berg LH, Franssen H. Activity-dependent conduction block in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2011;300:33-8.
163. Kiernan MC, Lin CS, Burke D. Differences in activity-dependent hyperpolarization in human sensory and motor axons. J Physiol 2004;558:341-9.
164. Howells J, Trevillion L, Bostock H, et al. The voltage dependence of I(h) in human myelinated axons. J Physiol 2012;590:1625-40.
165. Eftimov F, Liesdek MH, Verhamme C, et al. Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol 2014;14:72.
166. Hall ED, Baker T, Riker WF Jr. Glucocorticoid effects on spinal cord function. J Pharmacol Exp Ther 1978;206:361-70.
167. Braughler JM, Hall ED. Acute enhancement of spinal cord synaptosomal (Na+ + K+)- ATPase activity in cats following intravenous methylprednisolone. Brain Res 1981;219:464-9.
168. Hall ED. Glucocorticoid effects on the electrical properties of spinal motor neurons. Brain Res 1982;240:109-16.
169. Nordsborg N, Thomassen M, Lundby C, et al. Contraction-induced increases in Na+-K+-ATPase mRNA levels in human skeletal muscle are not amplified by activation of additional muscle mass. Am J Physiol Regul Integr Comp Physiol 2005;289:R84-91.